Amendment One to Licence of TechnologyLicence of Technology Agreement • May 9th, 2018 • Achieve Life Sciences, Inc. • In vitro & in vivo diagnostic substances
This Amendment One to Licence of Technology Agreement (this “Amendment”) is entered into as of this 22nd day of January 2018 (the “Amendment Effective Date”), by and between The University of Bristol, Senate House, Tyndall Avenue, Bristol, BS8 1TH, England (“Licensor”) and Achieve Life Sciences, Inc., a Delaware corporation having its principal place of business at 19820 North Creek Parkway, Suite 201, Bothell, Washington, 98011 (“Licensee”). Licensor and Licensee are each referred to herein a “Party” or, collectively, as the “Parties.” Capitalized terms used herein and not defined shall have the meaning assigned to them in the Agreement.
Amendment One to Licence of TechnologyLicence of Technology Agreement • May 23rd, 2018 • Achieve Life Sciences, Inc. • In vitro & in vivo diagnostic substances
This Amendment One to Licence of Technology Agreement (this “Amendment”) is entered into as of this 22nd day of January 2018 (the “Amendment Effective Date”), by and between The University of Bristol, Senate House, Tyndall Avenue, Bristol, BS8 1TH, England (“Licensor”) and Achieve Life Sciences, Inc., a Delaware corporation having its principal place of business at 19820 North Creek Parkway, Suite 201, Bothell, Washington, 98011 (“Licensee”). Licensor and Licensee are each referred to herein a “Party” or, collectively, as the “Parties.” Capitalized terms used herein and not defined shall have the meaning assigned to them in the Agreement.
AMENDMENT NO. 1 TO LICENCE OF TECHNOLOGY AGREEMENTLicence of Technology Agreement • August 8th, 2023 • PepGen Inc. • Pharmaceutical preparations
This Amendment No. 1 to the Agreement (this “Amendment”), effective as of 12th February 2021 (the “Amendment Effective Date”), is made by and between Oxford University Innovation Limited (Company Registration No. 2199542) whose registered office is a University Offices, Wellington Square, Oxford OX1 2JD, England (“OUI”); Medical Research Council, as part of United Kingdom Research and Innovation (also known as UK Research and Innovation) a body corporate established pursuant to section 91 of the Higher Education and Research Act 2017 whose address is Polaris House, North Star Avenue, Swindon SN2 1FL, United Kingdom (“MRC”); and PepGen Limited (Company Registration No. 11170794) whose registered office is at Bioescalator, Innovation Building, The Old Road Campus, Roosevelt Drive, Headington, Oxford OX3 7FZ (the “Licensee”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
